| Literature DB >> 36118358 |
Yujie Lu1, Mingwei Zhao2, Jiayuan Mo1, Ganqiu Lan1, Jing Liang1.
Abstract
Piglets are susceptible to weaning stress, which weakens the barrier and immune function of the intestinal mucosa, causes inflammation, and ultimately affects animal growth and development. Ellagic acid (EA) is a natural polyphenol dilactone with various biological functions. However, The mechanisms underlying the effects of EA on animal health are still poorly known. Herein, we examined whether dietary supplementation with EA has a positive effect on growth performance, intestinal health, immune response, microbiota, or inflammation in weaned piglets. Sixty weaned piglets (age, 30 days) were randomly divided into two groups: the control group (basic diet) and the test group (basic diet + 500 g/t EA). The pigs were fed for 40 days under the same feeding and management conditions, and the growth performance of each individual was measured. At the end of the feeding period, samples were collected from the small intestinal mucosa for further analysis. Using these tissues, the transcriptome sequences and intestinal microbial diversity were analyzed in both groups. An inflammation model using small intestinal mucosal epithelial cells (IPEC-J2) was also constructed. Dietary EA supplementation significantly increased the average daily weight gain (ADG) and reduced diarrhea rate and serum diamine oxidase (DAO) levels of weaned piglets. Transcriptome sequencing results revealed 401 differentially expressed genes in the jejunum mucosal tissue of pigs in the control and test groups. Of these, 163 genes were up-regulated and 238 were down-regulated. The down-regulated genes were significantly enriched in 10 pathways (false discovery rate < 0.05), including seven pathways related to immune response. The results of bacterial 16s rDNA sequencing show that EA affects the composition of the intestinal microbiota in the cecum and rectum, and reveal significant differences in the abundances of Prevotella_9, Lactobacillus delbrueckii, and Lactobacillus reuteri between the test and control groups (P < 0.05). Experiments using the inflammation model showed that certain doses of EA promote the proliferation of IPEC-J2 cells, increase the relative mRNA expression levels of tight junction-related proteins (ZO-1 and Occludin), improve the compactness of the intestine, reduce the expression of inflammatory factors TNF-α and IL-6, and significantly reduce LPS-induced inflammation in IPEC-J2 cells. In conclusion, we found for the first time that dietary supplementation of EA affects the gut immune response and promotes the beneficial gut microbiota in weaned piglets, reduces the occurrence of inflammatory responses, and thereby promotes the growth and intestinal health of piglets.Entities:
Keywords: ellagic acid; immune response; inflammation; intestinal mucosa; pig
Year: 2022 PMID: 36118358 PMCID: PMC9478910 DOI: 10.3389/fvets.2022.980271
Source DB: PubMed Journal: Front Vet Sci ISSN: 2297-1769
Figure 1The differentially expressed gene map. (A) Is the volcano map of differentially expressed gene, (B) is the heatmap of differentially expressed gene.
The GO and KEGG pathways of RNA-Seq.
|
|
|
|
|
|
|---|---|---|---|---|
| GOTERM_BP_DIRECT | GO:0031295~T cell costimulation | 0.0034 | 5 | SPN, TMIGD2, TNFSF14, CD5, CD3E |
| GOTERM_BP_DIRECT | GO:0006955~immune response | 0.0034 | 12 | CXCL11, TMIGD2, TNFSF14, OAS2, CCL20, CCL5, TNFRSF9, GZMB, XCL1, B2M, LAT, CD244 |
| GOTERM_CC_DIRECT | GO:0009897~external side of plasma membrane | 0.0060 | 9 | SPN, CD200R1, CD8B, CD8A, CD5, TNFRSF9, CD69, CD3E, CD244 |
| GOTERM_CC_DIRECT | GO:0001772~immunological synapse | 0.0072 | 5 | LCK, CD37, CD3E, CORO1A, LAT |
| KEGG_PATHWAY | ssc04060:Cytokine-cytokine receptor interaction | 0.0238 | 11 | CXCL11, TNFSF14, CCL20, CCL5, TNFRSF9, IL2RB, IL21R, ACKR3, IL2RG, IL9R, CXCL16 |
| KEGG_PATHWAY | ssc04660:T cell receptor signaling pathway | 0.0238 | 8 | CD8B, CD8A, LCK, FYN, CD247, FOS, CD3E, LAT |
| KEGG_PATHWAY | ssc04650:Natural killer cell mediated cytotoxicity | 0.0238 | 8 | LCK, SH2D1B, PRF1, GZMB, FYN, CD247, LAT, CD244 |
| KEGG_PATHWAY | ssc05340:Primary immunodeficiency | 0.0451 | 5 | CD8B, CD8A, LCK, IL2RG, CD3E |
| GOTERM_BP_DIRECT | GO:0008360~regulation of cell shape | 0.0481 | 7 | FGR, SEMA4D, SH3KBP1, WIPF3, PLEKHO1, FYN, CORO1A |
| GOTERM_BP_DIRECT | GO:0042127~regulation of cell proliferation | 0.0497 | 8 | FGR, CNN2, CXCL11, NOS2, LCK, TNFRSF9, FYN, SGK1 |
Figure 2RT-qPCR validation of the selected seven genes. SLC25A24 solute carrier family 25 member 24; ECH1, enoyl-CoA hydratase 1; ACOX1, acyl-CoA oxidase 1; GCG, glucagon; GIP, gastric inhibitory polypeptide; PYY, peptide YY; SLC5A10, solute carrier family 5 member 10.
Figure 3The α diversity analysis results. (A) Cecum Shannon index; (B) Rectum Shannon index; (C) Cecum Chao 1 index; (D) Rectum Chao 1 index.
Figure 4The β diversity analysis results. (A) Weighted Unifrac PCoA scatter plot; (B) Jaccard PCoA scatter plot.
Figure 5Taxonomy stack distribution of various species. (A) Taxonomy stack distribution of phylum level; (B) Taxonomy stack distribution of genus level; (C) Taxonomy stack distribution of species level.
Figure 6LEfSe analysis diagram of cecum.
Figure 7LEfSe analysis diagram of rectum.
Figure 8PICRUSt function prediction chart. (A) Cecum; (B) Rectum.
Effect of ellagic acid on IPEC cell proliferation.
|
|
| ||
|---|---|---|---|
|
|
|
| |
| 0 | 0.594 ± 0.112 | 0.638 ± 0.03 | 0.768 ± 0.013 |
| 10 | 0.591 ± 0.033 | 0.748 ± 0.082 | 0.824 ± 0.062* |
| 20 | 0.62 ± 0.086 | 0.807 ± 0.054** | 0.937 ± 0.074**# |
| 50 | 0.648 ± 0.06 | 0.94 ± 0.021** | 1.074 ± 0.021** |
| 100 | 0.695 ± 0.006*# | 1.033 ± 0.06** | 1.096 ± 0.011** |
Compared with the control group, * means significant difference (P < 0.05), ** means extremely significant difference (P < 0.01); compared with the concentration is 10 μg / ml group, # means significant difference (P < 0.05), ## means extremely significant difference (P < 0.01).
Effect of LPS on IPEC cell proliferation.
|
|
| ||
|---|---|---|---|
|
|
|
| |
| 0 | 0.613 ± 0.109 | 0.764 ± 0.073 | 0.765 ± 0.109 |
| 0.1 | 0.583 ± 0.008 | 0.699 ± 0.055* | 0.634 ± 0.053* |
| 1 | 0.482 ± 0.084 | 0.602 ± 0.068** | 0.526 ± 0.111** |
| 10 | 0.336 ± 0.117* | 0.363 ± 0.052** | 0.352 ± 0.056** |
Compared with the control group, * means significant difference (P < 0.05), ** means extremely significant difference (P < 0.01).
Figure 9The effect of ellagic acid on LPS-induced IPEC-J2 inflammatory cell viability. Compared with the control group, ** means extremely significant difference (P < 0.01); compared with the LPS group, ## means extremely significant difference (P < 0.01).
Figure 10ZO-1 and Occludin expression levels of IPEC-J2 cells treated with different concentrations of EA. (A) The expression levels of ZO-1; (B) the expression levels of Occludin. Compared with the control group, * means significant difference (P < 0.05).
Figure 11The expression levels of TNF-α and IL-6 mRNAs in LPS-induced IPEC-J2 cells treated with different concentrations of EA. (A) The expression levels of TNF-α mRNA; (B) the expression levels of IL-6 mRNA. Compared with the control group, ** means extremely significant difference (P < 0.01); compared with the LPS group, # means significant difference (P < 0.05), ## means extremely significant difference (P < 0.01).